EW Stock Overview
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Price-To-Earnings ratio (33.4x) is below the Medical Equipment industry average (35.9x)
Risk Analysis
No risks detected for EW from our risk checks.
My Notes
NewNotes are coming soon
Edwards Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$84.51 |
| 52 Week High | US$131.10 |
| 52 Week Low | US$67.13 |
| Beta | 1.01 |
| 1 Month Change | 10.51% |
| 3 Month Change | 23.30% |
| 1 Year Change | -24.67% |
| 3 Year Change | 9.09% |
| 5 Year Change | 100.78% |
| Change since IPO | 6,046.18% |
Recent News & Updates
Edwards Lifesciences slips as Piper downgrades on challenging setup
Jan 30Edwards Lifesciences: Short-Term Growth Worries Have Created An Opportunity
Jan 18Recent updates
Edwards Lifesciences slips as Piper downgrades on challenging setup
Jan 30Edwards Lifesciences: Short-Term Growth Worries Have Created An Opportunity
Jan 18Edwards Lifesciences: Catalysts For 2023 And Beyond
Dec 30Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 28
Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Dec 16Edwards Lifesciences CEO Michael Mussallem to retire
Dec 08Edwards Lifesciences (NYSE:EW) Knows How To Allocate Capital
Dec 04Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 22Edwards Lifesciences down 11% after Q3 misses, revised 2022 EPS guidance
Oct 27Edwards Lifesciences (NYSE:EW) Seems To Use Debt Rather Sparingly
Sep 22Edwards Lifesciences wins FDA approval for PASCAL transcatheter valve repair system
Sep 15Why Edwards Lifesciences Corporation (NYSE:EW) Could Be Worth Watching
Sep 10Edwards Lifesciences (NYSE:EW) Knows How To Allocate Capital
Aug 29Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Aug 17Edwards Lifesciences: Stretched Valuation And Bearish Resistance In Play
Aug 15Edwards Lifesciences stock down ~6% after hours on Q2 results miss, slashed FY guidance
Jul 28Edwards Lifesciences (NYSE:EW) Could Easily Take On More Debt
Jun 13Edwards Lifesciences: Seeking 60% Upside For Potential Exit At $160 Per Share
Jun 02Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Jun 02Capital Investment Trends At Edwards Lifesciences (NYSE:EW) Look Strong
May 22Is Now The Time To Put Edwards Lifesciences (NYSE:EW) On Your Watchlist?
May 10Edwards Lifesciences Corporation (NYSE:EW) Shares Could Be 33% Above Their Intrinsic Value Estimate
Apr 29Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Mar 14Edwards Lifesciences: High Revenue Growth Already Priced In
Mar 14Should You Investigate Edwards Lifesciences Corporation (NYSE:EW) At US$106?
Feb 20With EPS Growth And More, Edwards Lifesciences (NYSE:EW) Is Interesting
Feb 09Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
Jan 28Edwards LifeSciences: When Even A Pandemonium Makes Room
Jan 15Many Would Be Envious Of Edwards Lifesciences' (NYSE:EW) Excellent Returns On Capital
Jan 06Edwards Lifesciences (NYSE:EW) Could Easily Take On More Debt
Dec 13What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing?
Nov 17With EPS Growth And More, Edwards Lifesciences (NYSE:EW) Is Interesting
Nov 05Many Would Be Envious Of Edwards Lifesciences' (NYSE:EW) Excellent Returns On Capital
Sep 30Is Edwards Lifesciences (NYSE:EW) Using Too Much Debt?
Sep 06At US$111, Is Edwards Lifesciences Corporation (NYSE:EW) Worth Looking At Closely?
Aug 12Does Edwards Lifesciences (NYSE:EW) Deserve A Spot On Your Watchlist?
Jul 31Edwards Lifesciences: TAVR And TMTT Strengths Key Growth Levers
Jul 28Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Jun 06Edwards Lifesciences gets FDA clearance for hypotension prediction index software
Jun 01Shareholder Returns
| EW | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 8.2% | 4.7% | 2.9% |
| 1Y | -24.7% | -8.4% | -8.5% |
Return vs Industry: EW underperformed the US Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: EW underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| EW volatility | |
|---|---|
| EW Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: EW is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: EW's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 15,700 | Mike Mussallem | https://www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy.
Edwards Lifesciences Corporation Fundamentals Summary
| EW fundamental statistics | |
|---|---|
| Market Cap | US$52.25b |
| Earnings (TTM) | US$1.52b |
| Revenue (TTM) | US$5.38b |
34.3x
P/E Ratio9.7x
P/S RatioIs EW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EW income statement (TTM) | |
|---|---|
| Revenue | US$5.38b |
| Cost of Revenue | US$1.08b |
| Gross Profit | US$4.30b |
| Other Expenses | US$2.78b |
| Earnings | US$1.52b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.46 |
| Gross Margin | 79.93% |
| Net Profit Margin | 28.28% |
| Debt/Equity Ratio | 10.3% |
How did EW perform over the long term?
See historical performance and comparison